Our results showed both a nonsignificant effect of SGLT2 inhibitors on cancer mortality or progression and a nonsignificant effect of SGLT2 inhibitors on performance status, inflammatory markers, and malnutrition. This evidence concerns the gene SLC5A2 and cancer.